Engineered anti-PDL1 with IFNalpha targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Meng CY, Sun S, Liang Y, Xu H, et al. Gut 2023;72:1544-1554.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Meng CY, Sun S, Liang Y, Xu H, et al. Engineered anti-PDL1 with IFNalpha targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut 2023;72:1544-1554.
PMID: 36316098